Atlas Trials

Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC

Clinical trial NCT05668650 · UNKNOWN

Trial details

NCT number
NCT05668650
Sponsor
Laboratorio Elea Phoenix S.A.
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Non Small Cell Lung Cancer Metastatic
Start date
2023-08-15
Primary completion
2024-08-01
Enrollment
174

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.